- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001993
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
The primary objective of this study is to determine the preliminary efficacy and tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic HIV+ patients with 200 to 500 CD4+ cells/mm3.
The secondary objective is to determine the pharmacokinetics and bioavailability of both SC-48334 and AZT, when administered together, in symptomatic HIV+ patients with 200 - 500 CD4+ cells/mm3.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 331361013
- Univ of Miami School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Infectious Diseases Research Clinic / Indiana Univ Hosp
-
-
Ohio
-
Columbus, Ohio, United States, 432101228
- Ohio State Univ Hosp Clinic
-
-
South Carolina
-
West Columbia, South Carolina, United States, 29169
- Julio Arroyo
-
-
Washington
-
Seattle, Washington, United States, 981224304
- Univ of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Medications for the prophylaxis of opportunistic infections, such as:
- Aerosolized pentamidine.
- Trimethoprim/sulfamethoxazole.
- Nystatin.
- Clotrimazole.
- Anti-mycobacterial agents.
- Ganciclovir.
- Topical acyclovir.
Patients must have the following:
- CD4+ cells counts = or > 200 < 500 /cell mm3.
- For purposes of inclusion the absolute CD4+ cell count must be = or > 200 < 500 cells/mm3 on the first sample and = or > 190 < 510 cells/mm3 on the second sample.
- Have at least one of the following:
- Oral candidiasis.
- Herpes zoster during the last 3 years.
- Oral hairy leukoplakia during the past three years.
- Chronic ( > 30 day period), recurrent seborrheic dermatitis, or topical, pruritic folliculitis (itchy bumps).
- Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight.
- Chronic fatigue present for the past 6 months, which has interfered with normal activity at least 1 to 2 times per week.
- HIV antibody positive as determined by federally licensed Enzyme-linked Immunosorbent Assay (ELISA).
- Documented, written informed consent must be obtained prior to admission to the study.
Prior Medication:
Allowed for no more than 12 weeks prior to study entry:
- Zidovudine (AZT).
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Malignancies, with the exception of basal cell carcinoma.
- Significant organ dysfunction.
Concurrent Medication:
Excluded:
- All anti-retroviral drugs with the exception of Zidovudine. Cancer chemotherapeutic agents.
- Anti-metabolites and alkylating agents.
- All investigational non-FDA approved drugs.
Patients with the following are excluded:
- Clinically significant diarrhea (> 3 liquid stools per day for > 7 days) without definable cause, within 6 months prior to enrollment).
- Diarrhea, as above, with known, non-HIV related cause occurring within one month prior to enrollment.
- Meets CDC criteria for AIDS classification.
- Chronic fever (> 38.5 C persisting for more than 14 consecutive days, or for more than 15 days in any 30-day interval prior to study entry).
- Malignancies, with the exception of basal cell carcinoma.
- Significant organ dysfunction.
- Known hypersensitivity to SC-48334 or related compounds.
- History of lactose intolerance.
Prior Medication:
Excluded within 30 days of study entry:
- Any investigational medication.
- Treatment with a drug (other than Zidovudine) with anti-HIV activity.
- Excluded for > 12 weeks prior to study entry:
- Zidovudine (AZT).
- Excluded within 90 days of study entry:
- Ribavirin.
- Excluded within 6 months of study entry:
- Cancer chemotherapy.
- Excluded:
- Treatment with SC-48334.
Prior Treatment:
Excluded within 30 days of study entry:
- Electron beam radiation.
- Excluded within 6 months prior to study entry:
- Required HIV-related blood transfusions.
- Whole body radiation.
Current use of illicit substances; or current abuse of alcohol, the use of which would limit compliance with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Glycoside Hydrolase Inhibitors
- Zidovudine
- Miglustat
Other Study ID Numbers
- 057A
- NS8-90-02-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Zidovudine
-
Glaxo WellcomeUnknownHIV InfectionsUnited States
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV Infections | PregnancyThailand
-
Glaxo WellcomeCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Glaxo WellcomeCompleted
-
Glaxo WellcomeCompletedHIV Infections | LipodystrophyUnited States
-
Universidad Peruana Cayetano HerediaMerck Sharp & Dohme LLCCompletedHTLV-I Infections | Tropical Spastic ParaparesisPeru
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of...Completed
-
ViiV HealthcareCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV InfectionsUnited States, Puerto Rico